A. Hanschmann

发表

Antihyperalgesic and analgesic properties of the N‐methyl‐d‐aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia

R. Treede, W. Magerl, T. Klein, 2008, European journal of pain.

Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin®) injections in blepharospasm

J. Jankovic, H. Fernandez, D. Truong, 2013, Journal of Neural Transmission.

Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm—A randomized trial

J. Jankovic, C. Comella, A. Hanschmann, 2011, Movement disorders : official journal of the Movement Disorder Society.

IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated

J. Jankovic, C. Comella, V. Evidente, 2014, Journal of the Neurological Sciences.

Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia

J. Jankovic, C. Comella, D. Truong, 2011, Journal of the Neurological Sciences.

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects

Y. Otaka, Y. Masakado, R. Kaji, 2020, Frontiers in Neurology.

Safety Profile and Lack of Immunogenicity of IncobotulinumtoxinA in Pediatric Spasticity and Sialorrhea: A Pooled Analysis

F. Heinen, D. Gaebler-Spira, S. Berweck, 2022, Toxins.

Satisfaction With Botulinum Toxin Treatment In Post-Stroke Spasticity: Results From Two Cross-Sectional Surveys Of Patients And Physicians (P1.143)

D. Bensmail, A. Hanschmann, 2014 .

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin®) in cervical dystonia

H. Fernandez, M. LeDoux, C. Comella, 2013, Journal of Neural Transmission.

Facial skin revitalization with CPM®-HA20G: an effective and safe early intervention treatment

M. Kerscher, M. Hofmann, T. Reuther, 2019, Clinical, cosmetic and investigational dermatology.

Safety and efficacy of repeat long-term incobotulinumtoxinA treatment for lower limb or combined upper/lower limb spasticity in children with cerebral palsy

F. Heinen, D. Gaebler-Spira, E. Dabrowski, 2021, Journal of pediatric rehabilitation medicine.

IncobotulinumtoxinA for the treatment of lower-limb spasticity in children and adolescents with cerebral palsy: A phase 3 study

P. Kaňovský, F. Heinen, D. Gaebler-Spira, 2021, Journal of pediatric rehabilitation medicine.

F. Heinen, D. Gaebler-Spira, E. Dabrowski, 2022, Journal of pediatric rehabilitation medicine.

IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study

E. Elovic, M. Munin, A. Brashear, 2018, Advances in Therapy.

Safety of IncobotulinumtoxinA in the Treatment of Facial Lines: Results From a Pooled Analysis of Randomized, Prospective, Controlled Clinical Studies

G. Sattler, W. Coleman, M. Hast, 2017, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

FP50-TH-06 Efficacy and safety of NT 201 (Xeomin®, botulinum neurotoxin free from complexing proteins) in cervical dystonia

J. Jankovic, C. Comella, D. Truong, 2009, Journal of the Neurological Sciences.

Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects

J. Jankovic, D. Mitsikostas, A. Dekundy, 2021, Current medical research and opinion.

SUSTAINED EFFICACY OF INCOBOTULINUMTOXINA FOLLOWING REPEATED INJECTIONS FOR UPPER-LIMB POST-STROKE SPASTICITY: A POST HOC ANALYSIS

P. Kaňovský, E. Elovic, M. Munin, 2020, Journal of rehabilitation medicine.

Satisfaction with botulinum toxin treatment in post-stroke spasticity: Results from two cross-sectional surveys of patients and physicians

D. Bensmail, A. Hanschmann, 2013, Journal of the Neurological Sciences.

Randomized, placebo‐controlled trial of incobotulinumtoxina for upper‐limb post‐stroke spasticity

P. Kaňovský, E. Elovic, M. Munin, 2015, Muscle & nerve.

Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians)

J. Wissel, D. Bensmail, A. Hanschmann, 2014, Journal of medical economics.

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults (P12-11.007)

M. Hast, M. Althaus, Petr Kaňovský, 2023, Wednesday, April 26.

Efficacy and safety of incobotulinumtoxinA in post-stroke upper-limb spasticity in Japanese subjects: results from a randomized, double-blind, placebo-controlled study (J-PURE)

S. Saeki, E. Saitoh, Y. Masakado, 2020, Journal of Neurology.

IncobotulinumtoxinA for upper- and lower-limb spasticity in Japanese patients

E. Saitoh, T. Fujiwara, Y. Masakado, 2020, Current medical research and opinion.

Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis

P. Kaňovský, E. Elovic, C. Marciniak, 2021, Frontiers in Neurology.

Pooled Safety Analysis of IncobotulinumtoxinA in the Treatment of Neurological Disorders in Adults

M. Hast, M. Althaus, A. Hanschmann, 2023, Journal of the Neurological Sciences.

Efficacy and Safety of IncobotulinumtoxinA in the Treatment of Lower Limb Spasticity in Japanese Subjects

Y. Otaka, Y. Masakado, R. Kaji, 2022, Frontiers in Neurology.

IncobotulinumtoxinA Treatment in Upper‐Limb Poststroke Spasticity in the Open‐Label Extension Period of PURE: Efficacy in Passive Function, Caregiver Burden, and Quality of Life

E. Elovic, M. Munin, A. Brashear, 2020, PM & R : the journal of injury, function, and rehabilitation.